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Abstract
Background: Interleukin-6 is a multifunctional cytokine with well-defined pro- and anti-inflammatory properties. Binding to the receptor complex 
composed of specific interleukin-6-receptor (IL-6R) and transmembrane glycoprotein gp130, it stimulates various signalling cascades. Intracellular 
signal transduction involves both STAT-dependent, and STAT-independent mechanisms. IL-6R exists in the soluble and the membrane-bound forms, 
thus were described the classical signalling and the trans-signalling pathways. The pro-inflammatory response occurs via trans-signalling, while the anti-
inflammatory effects are mediated by classical signalling pathway. IL-6 is produced by cardiovascular components. The high levels of IL-6 are identified 
in the inflammatory diseases. 
Conclusions: IL-6 expresses the well-defined pro- and anti-inflammatory properties. The experimental studies have revealed classic signalling pathway 
with regenerative and anti-inflammatory effects (via the membrane-bound IL-6R), and trans-signalling responsible for the pro-inflammatory response 
(via the soluble form sIL-6R). The intracellular signal transduction involves the activation of STATs, MAPK, and PI3K cascades. It has been proved that 
in the cardiovascular pathologies the serum levels of IL-6 correlate with the disease severity and the degree of myocardial damage, being the indicator of 
heart disease and a predictive factor of adverse outcomes.
Key words: interleukin-6, cytokine, trans-signalling, cardiac ischemia.
Introduction
Cytokines are glycosylated proteins involved in the in-
tercellular communication. The interleukin-6 (IL-6) type 
of cytokines participates in the inflammation, regulates 
the target cells differentiation, proliferation, migration and 
apoptosis [1], and is a key factor in coordinating innate and 
acquired immune response [2].
Its biological effect is achieved by homo- or heterodi-
merisation of glycoprotein 130 (gp130) [3]. The transduc-
tion of IL-6 type cytokine signal involves the activation of 
Janus (Jak) kinases, followed by the phosphorylation of 
transcription factors STAT [4], as well as triggering MAPK 
and PI3K signalling pathways [5]. The deregulation of both 
the IL-6-mediated signal transduction mechanism, and 
the intercellular communication processes generates neo-
plasms, severe autoimmune and inflammatory diseases [6].
Interleukin-6 (IL-6) is a small glycoprotein that activates 
the cells via the heterodimeric signalling complex, con-
sisting of the alpha receptor (IL-6R) and the beta subunit 
for signal transduction, represented by glycoprotein 130 
(gp130) common to all cytokines type IL-6 [7].
IL-6-mRNA encodes the 212 amino acid protein, in-
cluding the 29 amino acid signalling peptide. The secreted 
protein contains 184 amino acids (21 kDa) [8], of which 107 
are well defined in the final structure, while 18 N-end amino 
acids and 8 amino acids from AB loop have no visible elec-
tron density [9]. There have been described the different 21-
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28 kDa isoforms, formed due to the various N-linked glyco-
sylation, which determines the stability and half-life of the 
protein [10]. IL-6 is synthesized and secreted by the most 
cells, including T cells, fibroblasts, monocytes, and endothe-
liocytes.
The IL-6 conformation consists of 4 long alpha-helixes 
(A, B, C, D) [8], with the typical “up-up-down-down” ar-
rangement, that is common to all IL-6 type cytokines [2]. 
The attachment to the IL-6R / gp130 receptor complex takes 
place through three well-differentiated contact sites: *site 1 
(binds IL-6R), *site 2 (attaches gp130 between the domains 
2 and 3), and *site 3 (contacts the immunoglobulin-like 
domain 1 of gp130) [2]. The site 1 is formed by the C-end 
groups of D-helix and the C-end part of the AB loop, and 
determines the specificity of binding to IL-6R. The site 2, 
consisting of the middle sequences of the A and C helixes, 
and the site 3, formed by the N-terminal part of the AB loop 
(3a) and the C-end of the D helix (site 3b), are required for 
the recruitment of 2 molecules of gp130 [2].
The synthesis of IL-6-mRNA is regulated at both the 
transcriptional, and the post-transcriptional levels. The key 
role in IL-6 expression is attributed to nuclear transcrip-
tion factor kappa B (NF-κB), activated by the bacterial li-
popolysaccharides, pro-inflammatory cytokines (TNFα) or 
viruses [11].
Experimental studies have highlighted fact that a large 
number of microRNAs (miR) inhibit IL-6 expression, in-
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cluding miR-26a [12], miR-142 [13], miR-146a [14], miR-
187 [15], miR-200S [16], miR-329 [17].
Very low amounts of IL-6 (about 1-5 μg/ml) there are in 
the blood of healthy people. The high serum levels of IL-6 
are identified in the most of inflammatory and/or autoim-
mune diseases, reaching the μg/ml values in septic states 
[18]. IL-6 is the most potent activator of the synthesis of the 
acute phase proteins in hepatocytes, including the C-reac-
tive protein, and it is an important factor for tumor growth 
[19]. Kishimoto T. (2010) has suggested that IL-6 is a mark-
er of the continuous inflammation [20].
 IL-6 is also produced by cardiovascular components, 
such as endothelial cells, vascular smooth muscle and isch-
emic cardiomyocytes [21]. The expression of IL-6 is stimu-
lated by the C-reactive protein via the nuclear factor B (NF-
B), and inhibited by the nitric oxide (NO). It was proved the 
involvement of IL-6 in the cardiac metabolism regulation 
[22]. Yudkin J. et al. (2000) have shown the role of IL-6 in 
the pathogenesis and clinical development of atherosclerot-
ic vascular lesions [23].
 The high levels of circulating IL-6 are associated with 
the increased risk of mortality and poor clinical outcome in 
the patients with unstable angina [24]. Clinically was con-
firmed that the IL-6 concentrations not only correlate with 
the severity of the disease, but are also the important predic-
tors of adverse outcomes. It has been shown that the pro-
inflammatory cytokines participate in the destabilization 
and disruption of the atherosclerotic plaque in the coronary 
arteries, by stimulating the expression of matrix metallopro-
tease that are responsible for the vascular remodelling and 
the plaque disorganization [25].
The increased expression of myocardial IL-6 is associ-
ated with the progression of heart failure, so IL-6 can be a 
true indicator of heart damage [26]. The experimental data 
show evidence that pro-inflammatory cytokines can depress 
myocardial contractility and are responsible for the cardio-
vascular disease development and evolution [22]. In the 
patients with acute coronary syndrome the serum levels of 
IL-6 correlate with the severity of myocardial lesions [27].
IL-6 is involved in the control of vascular permeabil-
ity by stimulating the production by the fibroblasts of the 
vascular endothelial growth factor (VEGF) that acts on the 
endothelial cells, as well as by enhanced collagen synthesis 
[28]. There has been identified the association of IL-6 with 
endothelial cell activation markers, cell adhesion molecules 
(VCAM1, ICAM1) and von Willebrandt factor [29]. In 2013 
Zamani P. et al. (2013) have confirmed that elevated levels of 
VCAM1 correlate with the increased risk of coronary events 
in patients with acute coronary syndrome [27].
The published data have proved that IL-6 contributes to 
the resorption of acute neutrophil infiltration by inducing 
apoptosis of neutrophils [30]; while the T-cell apoptosis is 
prevented by activating the STAT3-dependent anti-apoptot-
ic factors (Bcl2, Bclx1) [31].
The receptor complex that mediates the biological re-
sponse of IL-6 consists of the transmembrane glycopro-
tein type I for IL-6 binding, called alpha-IL-6R (CD126 or 
gp80), and transmembrane protein type I for signal trans-
duction (beta-subunit, CD130 or gp130) [2]. The expression 
of gp130 is characteristic of all body cell types, whereas the 
expression of αIL-6R has a limited character and is char-
acteristic of hepatocytes, megakaryocytes, and some leu-
kocyte subpopulations (monocytes, macrophages, B and T 
cells) [32].
The experimental functional and structural studies sug-
gest that IL-6 can form both the hexameric, composed of 2 
molecules of IL-6, IL-6R and gp130 (IL-62/IL-6R2/gp1302) 
[33], and the tetrameric (IL-6/IL-6R/gp1302) signalling 
complexes [34]. Viswanathan S. et al. (2002) have shown 
that the low IL-6 concentrations favour the formation of the 
tetrameric complexes, whereas the high concentrations of 
IL-6 will lead to the formation of the hexameric complexes 
[35].
Interleukin-6 receptor (IL-6R) represents the 80 kDa gly-
cosylated membrane protein [36]. The immunoglobulin-
like domain of the human IL-6R does not participate in the 
IL-6 binding, but it is responsible for the receptor stability. 
The attachment of IL-6 to IL-6R is mediated by the specific 
sequences located in the domains 2 and 3 of IL-6R [2].
IL-6R exists in both the soluble and the membrane-
bound forms, which allow differentiating the classical sig-
nalling pathway (via the membrane-bound IL-6R) and the 
trans-signalling (through soluble (sIL-6R) receptor). In 
2012 in his studies, Rose-John S. mentioned that the trans-
signalling pathway represents the pro-inflammatory part of 
the IL-6 biological effect [8], while the classical signalling 
exhibits the anti-inflammatory and regenerative activity [1]. 
The experimental studies confirmed that the regenerative, 
protective and anti-inflammatory effects of IL-6 [37] are 
mediated through the membrane-bound IL-6R, which is 
responsible for the differentiation of pro-inflammatory M1 
macrophages into anti-inflammatory M2 macrophages [38]. 
Also via the classical signalling pathway IL-6 is involved in 
the hepatic regulation of the insulin sensitivity and glucose 
tolerance [39].
 Wilke C. et al. in 2011 highlighted the role of trans-sig-
nalling in the immune system adaptation, and the T cells 
recruitment, activation and apoptosis [40]. The target cells 
for trans-signalling are the stem cells: hematopoietic [41], 
nerve [42], smooth muscle [43], and embryonic [44]. The 
trans-signalling ensures the migration of the lymphocytes 
in the inflammation area [45]; it induces T cell prolifera-
tion and participates in the regulation of the adhesion cells 
expression in the endothelial cells [46].  
IL-6R can be cleaved proteolyticaly from the cell mem-
brane surface and produce the soluble form of IL-6R (sIL-
6R) [47]. Taga T. et al. (1989) have demonstrated that the 
cytosolic region and the transmembrane domain of IL-6 do 
not participate in the signalling mechanisms, so they have 
hypothesized that the formation of sIL-6R is a tool for in-
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volving the cells that possess only gp130 in the signalling 
pathways mediated by IL-6 [48].
 The soluble sIL-6R receptor is generated by two differ-
ent mechanisms: * the shedding of the membrane-bound 
receptor (90-99%) [2, 47]; * the alternative splicing (approx-
imately 1-10%) and the transcription of IL-6R-mRNA omit-
ting the exon 10 that encodes the transmembrane and cyto-
solic domains [47, 49]. The proteolytic cleavage of IL-6R is 
catalysed by the ADAM-10 and ADAM-17, Zn2+ metallo-
proteases (sheddases) [2, 50], the transmembrane proteins 
involved in the partial proteolysis of the membrane recep-
tors of the cytokines [51]. The cleavage site for ADAM-17 is 
located between Gln357 and Asp358 in the region adjacent 
to cell membrane [52], the complete cleavage of IL-6R from 
the cell surface occurs within 24 hours [47]. It was supposed 
that ADAM-10 is responsible for the slow cleavage, whereas 
ADAM-17 favours the rapid proteolysis of the membrane-
bound IL-6R [50]. In addition to the ADAM family of shed-
dases, the IL-6R also can be cleaved by the cathepsin G [53].
The biological activators of ADAM-17 are the pro-in-
flammatory cytokines (TNFα) [54], reactive C protein, the 
bacterial toxins (streptolysin O, hemophilin A) and metal-
loproteases, as well as the apoptotic pathways [55]. In 2011 
Scheller J. et al. have mentioned the decisive role of ADAM-
17 in the cancer genesis and inflammation [56]. The pub-
lished data demonstrated that the apoptosis-induced cleav-
age of IL-6R is caspase-dependent, and PKC/MAPK/ROS 
independent [2].
According to McFarland-Mancini M. et al. (2010) the 
main sources of sIL-6R are the hepatocytes and hemato-
poietic cells, as well as the immune cells (neutrophils, mac-
rophages) [57]. It has been hypothesized that the soluble 
forms of the receptor are the important regulators of the 
inflammatory processes [2]. 
The recent studies have found that the single base pair 
polymorphism determines the serum level of sIL-6R in hu-
mans. The substitution of adenine with cytosine leads to 
the replacement of Asp358 with Ala358 in the exon 9 of the 
IL-6 gene [58]. In some studies it has been mentioned the 
association of Asp358Ala variant with low risk of coronary 
events [59].
According to Scheller J. et al. (2011) the glycoprotein 130 
(gp130) is a membrane type I glycosylated protein with a 
molecular weight of 130-150 kDa, consisting of 6 extracellu-
lar domains, one transmembrane domain and one cytosolic 
domain. The N-terminus has the immunoglobulin-like do-
main (D1), followed by 2 cytokine binding domains (CBD, 
the domains 2 and 3) and 3 fibronectin (FN-III) domains 
(the domains 4-6) [2].  
In 2003 Boulanger M. et al. demonstrated that the im-
munoglobulin-like domain of gp130 ensures the interaction 
with IL-6R and the attachment to the IL-6 site 3 [35]. The 
cytokine binding domains (CBD2 and CBD3) of gp130 as-
sociate with IL-6 site 2. CBD2 located in the N-end region 
contains 2 pairs of Cys, which form inter-chain disulphide 
bonds, while CBD3 contains the Trp-Ser-X-Trp-Ser se-
quence [60]. The proximal membrane domains of gp130 are 
involved in the signal transduction to the cytosolic domain 
[2]. After the ligand binding, the domains 4 and 5 are rear-
ranged at an angle of 80° with the curve formation, thus the 
whole gp130 ectodomain acquires the structural conforma-
tion similar to a wide open «C» [61].
The receptor gp130 subunit has affinity for neither IL-6 
nor IL-6R [62]. Therefore, IL-6 can only fix and stimulate 
the cells that possess IL-6R, while the cells that have only 
gp130 are completely irresponsive to the IL-6 cytokine sig-
nals [63].
The myocardial ischemia/reperfusion induces the ex-
pression of gp130, associated with the stimulation of IL-6 
and IL-6R expression, thus confirming the role of the IL-6/
IL-6R/gp130 system in acute myocardial infarction [12].
Gp130 serves as the β-subunit of the receptor common 
for the IL-6 cytokine family. Recently have been described 
several soluble molecules (sgp130) with lower molecular 
mass [64], generated by: (1) shedding, (2) alternative splic-
ing, (3) the  addition of an exon consisting of 85 base pairs 
that alters the codons reading by forming a STOP-codon 
prior to the transmembrane domain coding sequence, (4) 
the deletion of an exon with new C-terminal sequence 
(NIASF) formation, followed by STOP-codon, or (5) the al-
ternative polyadenylation of the intron 10 resulting in new 
mRNA [65].
Due to the fact that the secreted IL-6 binds in the plas-
ma with sIL-6R, and with sgp130, it has been experimen-
tally proved that the soluble form of gp130 (sgp130) inhib-
its the trans-signalling pathway [66]. Jostok T. et al. (2001) 
have confirmed that sgp130 interacts only with sIL-6R in 
the presence of IL-6. The balance between the soluble and 
membrane forms of gp130 plays an important role in regu-
lating the biological effects of cytokines. When the amount 
of IL-6 exceeds the amount of sIL-6R and sgp130, IL-6 will 
act systemically [62].
The recent publications have demonstrated that the sin-
gle base pair polymorphism in the IL-6R gene manifested by 
the replacement of Gln258 with Ala, results in higher serum 
concentrations of sIL-6R, and is associated with reduced 
risk of coronary heart disease [67]. Boekholdt S. and Stroes 
E. (2012) have determined that the cleavage of membrane-
bound IL-6R on the surface of hepatocytes, monocytes and 
macrophages results in the loss of cell sensitivity to IL-6 me-
diated signals [68]. Scheller J. and Rose-John S. (2012) have 
assumed that high serum levels of sIL-6R increase the buffer 
capacity of the sIL-6R/sgp130 complex in the blood, thereby 
diminishing the systemic effects of IL-6 [69].
There has been shown that the single base pair polymor-
phism (G148R) in gp130 deregulates the function and sta-
bility of the protein, and it is associated with a low risk of 
acute myocardial infarction [70]. Elevated serum levels of 
sgp130 were identified in patients with heart failure, being 
associated with higher mortality rates. In 2007 Ichiki T. et al. 
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presented the data that in the patients with acute myocar-
dial infarction the serum levels of sgp130 were the highest 
at admission, and were followed by the decreasing in the 
post-infarction period [71]. At the same time, the patients 
with progressive heart failure have higher levels of sgp130 
compared to the patients with stable heart failure, so the 
sgp130 can be used to identify patients at high risk for the 
heart failure progression [72].
 Both the experimental animal studies, and in vitro mod-
elling, have highlighted the beneficial effect of sgp130 in ath-
erosclerosis as result of the trans-signalling pathway inhibi-
tion by the specific binding of the IL-6/sIL-6R heterodimer 
[62, 73]. It has been assumed that the higher levels of sgp130 
represent the compensatory response to increased IL-6 sig-
nalling in chronic ischemic disease and vascular remodel-
ling [73]. Moreno Velasquez I. et al. (2015) have shown the 
association of elevated serum levels of sgp130 with a 30% 
reduction in acute myocardial infarction incidence [74]. 
There was confirmed the hypothesis that in acute coronary 
syndromes the sgp130 changes correlate negatively with 
the severity of the inflammation [75]. The published results 
have suggested that sgp130 may be used as the prognostic 
biomarker in cardiac diseases [76].
 The classical signalling pathway starts with IL-6 attach-
ment to the membrane receptor αIL-6R, the formation of 
the signalling complex with the gp130 homodimer, the sig-
nal transduction and activation of the intracellular signal-
ling pathways [2].  The cells that express only gp130 can be 
stimulated by the IL-6/sIL-6R complex via the trans-signal-
ling pathway [77].
Cellular response to IL-6/sIL-6R complex differs sub-
stantially from the response to IL-6. This can be explained 
by: * the cell expresses more gp130 than IL-6; ** IL-6 is in-
ternalized faster compared to the IL-6/sIL-6R complex [78]. 
Experimentally has been demonstrated that the IL-6 affinity 
for IL-6R is 1nM, whereas the affinity of IL-6/sIL-6R com-
plex for gp130 is 100-fold greater [79].
The gp130 cytokine receptor does not possess intrinsic 
kinase activity. The first step in the intracellular transduc-
tion of the IL-6 signal is the activation of Janus (Jak) kinases 
(Jak1, Jak2 and Tyk2), that are non-covalently constitutive 
associated with the cytosolic tail of gp130. FERM domain 
ensures the interaction of Jak-kinases with gp130 [80]. The 
IL-6 binding to the specific receptor favours the induction 
of Jak-kinases by the tyrosine sequence phosphorylation, lo-
cated on the activation loop of C-terminal JH1 domain. The 
active Jak-kinases lead to phosphorylation of the distal tyro-
sine residues from the cytosolic part of gp130, which repre-
sent the recruitment sites for STAT (signal transductor and 
activator of transcription) factor. STAT1 or STAT3 mono-
mers attach to the distal phosphotyrozine residue, the tyro-
sine phosphorylation of STAT occurs, followed by homo- or 
heterodimerisation, the translocation of STAT dimers in the 
nucleus, N- and C-terminal acetylation, CBP/p300 interac-
tion, and the attachment to the promotor region of IL-6 in-
ducible gene [81]. Thus, the cytokines binding will induce 
the reorganization of the preformed receptor complexes 
and the successive cross-phosphorylation [2].
IL-6 activates the cascades STATs, MAPK, and PI3K 
[82]. The balance between activation of STAT3 and MAPK 
is crucial for the controlled proliferation of cells, and ul-
timately for the body's homeostasis [83]. This balance is 
regulated by the cytosolic Tyr759 of gp130; the tyrosine 
phosphorylation will reduce IL-6-dependent STAT3 acti-
vation [84], and induce MAPK activation [85]. At the same 
time, the phosphorylation of the gp130 Tyr759 residue is 
essential for the membrane IL-6-dependent recruitment of 
Gab-1 protein, which acts as the bridge between the cas-
cades MAPK, and PI3K, and the activated receptor com-
plex [86]. Chen R. et al. (1999) have concluded that the 
survival mechanisms are maintained via the activation of 
PI3K and Akt [87].
Conclusions
Interleukin-6 expresses the well-defined pro- and anti-
inflammatory properties. The experimental studies have re-
vealed classic signalling pathway with regenerative and an-
ti-inflammatory effects (via the membrane-bound IL-6R), 
and trans-signalling responsible for the pro-inflammatory 
response (via the soluble form sIL-6R). The intracellular sig-
nal transduction involves the activation of STATs, MAPK, 
and PI3K cascades. It has been proved that in the cardio-
vascular pathologies the serum levels of IL-6 correlate with 
the disease severity and the degree of myocardial damage, 
being the indicator of heart disease and a predictive factor 
of adverse outcomes.
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